Ultragenyx Pharmaceutical (NASDAQ:RARE) High to “Hold” at StockNews.com

Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) has been upgraded by StockNews.com from a “sell” to a “hold” rating in a note issued to investors on Friday.

A number of other research companies have also weighed in on RARE. JPMorgan Chase & Co. moved shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a price target of $132.00 for the company in a Friday 11 research note. February. Zacks Investment Research moved shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 price target for the company in a Tuesday, February 15 research note. Finally, Morgan Stanley lowered its price target on shares of Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a Friday, Feb. 11 research note. One financial analyst has assigned the stock a sell rating, four have issued a hold rating and nine have assigned the company’s stock a buy rating. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Buy” and an average target price of $123.60.

RARE stock traded down $2.11 by midday on Friday, hitting $65.41. 282,078 shares of the stock traded in hands, compared to its average volume of 421,731. Ultragenyx Pharmaceutical has a one-year low of $62.13 and a one-year high of $133.82. The stock has a market capitalization of $4.54 billion, a PE ratio of -9.75 and a beta of 1.69. The company has a 50-day moving average price of $69.81 and a two-hundred-day moving average price of $80.36.

(A d)

Small cap stocks – and penny stocks in particular – tend to march to the beat of their own beater.

Low-priced, “penny” stocks like these offer a great way to make money regardless of the direction of the markets as a whole…

Click here to see how you can get the names and stock symbols of the four penny stocks.

Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last released its results on Thursday, February 10. The biopharmaceutical company reported ($1.79) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of ($1.32) by ($0.47). Ultragenyx Pharmaceutical had a negative net margin of 129.20% and a negative return on equity of 44.24%. The company posted revenue of $83.39 million for the quarter, compared to analysts’ expectations of $83.68 million. In the same period a year earlier, the company posted ($1.34) earnings per share. The company’s revenue for the quarter was down 8.9% from the same quarter last year. As a group, stock analysts expect Ultragenyx Pharmaceutical to post earnings per share of -6.56 for the current year.

In related news, Insider John Richard Pignon sold 4,498 shares in a trade that took place on Tuesday, March 1. The shares were sold at an average price of $66.62, for a total value of $299,656.76. The sale was disclosed in an SEC filing, available at the SEC website. Also, VPE Camille L. Bedrosian sold 1,657 shares in a trade that took place on Sunday, January 30. The stock was sold at an average price of $66.30, for a total transaction of $109,859.10. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 14,008 shares of the company worth $913,819. Company insiders own 6.70% of the company’s shares.

A number of large investors have recently changed their stock holdings. Norges Bank acquired a new position in Ultragenyx Pharmaceutical in Q4 for a value of approximately $52,268,000. Barclays PLC increased its stake in Ultragenyx Pharmaceutical by 396.9% in the fourth quarter. Barclays PLC now owns 23,430 shares in the biopharmaceutical company worth $1,970,000 after buying an additional 18,715 shares during the period. JustInvest LLC increased its position in Ultragenyx Pharmaceutical by 113.2% in the 4th quarter. JustInvest LLC now owns 13,086 shares of the biopharmaceutical company worth $1,100,000 after purchasing an additional 6,947 shares last quarter. BlackRock Inc. increased its position in Ultragenyx Pharmaceutical by 1.0% in the fourth quarter. BlackRock Inc. now owns 3,484,652 shares of the biopharmaceutical company worth $293,025,000 after buying 34,099 additional shares last quarter. Finally, Goldman Sachs Group Inc. strengthened its position in Ultragenyx Pharmaceutical by 43.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 725,678 shares of the biopharmaceutical company worth $61,023,000 after buying an additional 219,470 shares last quarter. Institutional investors hold 97.52% of the company’s shares.

About Ultranyx Pharmaceutical (Get a rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous used for the treatment of mucopolysaccharidosis VII.

See also

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ: RARE)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Ultragenyx Pharmaceutical right now?

Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.

Although Ultragenyx Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here